# Moderna's first-quarter revenue surpassed estimates, driven by strong international COVID-19 vaccine sales.

*biotech · news · 2026-05-01 · The Economic Times*

## Key points

- Moderna's first-quarter revenue more than tripled to $389 million, driven by international COVID-19 vaccine sales.
- U.S. COVID-19 vaccine recommendations have become uncertain under Health Secretary Robert F. Kennedy Jr.
- Moderna received European approval for its combination COVID-flu vaccine, mCombriax, targeting a 2027 launch.
- Moderna forecasts Q2 revenue below analyst expectations, with a 50-50 split between U.S. and international sales.
- The company expects up to 10% revenue growth by 2026, with half from the U.S., down from 62% last year.

**Companies:** Moderna
**Countries:** United States, United Kingdom, Canada, Australia

[Read the full story on The Economic Times](https://economictimes.indiatimes.com/news/international/business/moderna-first-quarter-revenue-jumps-on-strong-overseas-covid-vaccine-sales/articleshow/130685033.cms)

---

Canonical: https://newsio.io/n/3067b6c9-8edd-41a0-a980-c27119c82a86/modernas-first-quarter-revenue-surpassed-estimates-driven-by-strong-internationa
Summarized by Newsio from The Economic Times. https://newsio.io/how-it-works